Dyslipidemia

← Back to Conditions

Category: Cardiovascular Health  |  Also addressed: Lipid Abnormalities, Abnormal Cholesterol, Lipid Disorder

What Is Dyslipidemia?

Dyslipidemia is a pattern of abnormal lipid markers that increases cardiovascular risk. The critical distinction in functional medicine is that the standard lipid panel captures only a fraction of the lipid-related cardiovascular risk picture and misses the markers that most accurately predict atherosclerosis progression and events. Total LDL-C is a particularly misleading single marker because it conflates LDL particle number, which is the actual atherogenic driver, with particle size, and a patient can have normal LDL-C with a dangerously elevated LDL particle number, or vice versa.

Why It Matters

Cardiovascular disease remains the leading cause of death in the United States, and dyslipidemia is its most modifiable measurable driver. But only when the right markers are evaluated. The standard lipid panel was designed to detect gross lipid abnormalities, not to characterize the full atherogenic particle burden that determines actual cardiovascular event risk.

Common Symptoms

Dyslipidemia is asymptomatic until advanced cardiovascular disease develops. The absence of symptoms does not indicate the absence of risk. Lab evaluation is the only reliable way to identify dyslipidemia and stratify cardiovascular risk. The following features frequently co-occur with dyslipidemia from shared upstream causes and should prompt lipid evaluation.

Root Causes: A Functional Medicine Perspective

Dyslipidemia is not a single condition but a set of distinct lipid patterns, each driven by a different upstream mechanism. Identifying which mechanism is dominant determines whether the primary intervention is metabolic, thyroid-directed, inflammatory, or nutritional.

Insulin Resistance: The Most Common Driver

Insulin resistance is the dominant driver of the most common dyslipidemia pattern in functional medicine patients: elevated triglycerides, low HDL, and elevated small dense LDL. Elevated insulin drives VLDL overproduction from the liver, increasing triglycerides. VLDL excess drives HDL degradation by cholesterol ester transfer protein activity, reducing HDL. The resulting triglyceride-enriched LDL particles are remodeled into the small dense phenotype by hepatic lipase. The triglyceride-to-HDL ratio above 2.0 in Caucasians is a simple and highly accurate surrogate for the atherogenic lipid triad from insulin resistance.

Hypothyroidism as a Statin-Refractory Mechanism

Thyroid hormone regulates LDL receptor expression in the liver. Hypothyroidism, including subclinical hypothyroidism with TSH above 2.5 mIU/L, reduces LDL receptor density, impairing LDL clearance and raising LDL-C and total cholesterol. This is the most common overlooked cause of statin-refractory hypercholesterolemia. The elevated LDL is from reduced hepatic clearance due to thyroid insufficiency, not from overproduction, and it responds to thyroid optimization rather than additional lipid-lowering medication.

Lp(a) Elevation: Genetically Determined Risk

Lipoprotein(a) is approximately 90% heritable and is not significantly modifiable by diet, statins, or most lifestyle interventions. Elevated Lp(a) above 50 mg/dL or 125 nmol/L independently doubles to quadruples cardiovascular and aortic valve disease risk. It is not included in standard lipid panels and most patients with elevated Lp(a) have never been tested. The primary management of elevated Lp(a) is aggressive risk factor reduction in all other modifiable domains including inflammation, blood pressure, insulin resistance, and homocysteine.

Inflammatory Amplification of Lipid Risk

Oxidized LDL is the actual atherogenic form that penetrates the arterial intima and initiates plaque formation. LDL oxidation is driven by systemic inflammation, omega-3 deficiency, and elevated homocysteine. A patient with normal LDL-C but elevated hs-CRP, homocysteine above 10, and an omega-3 index below 4% may have a higher actual atherosclerotic burden than a patient with moderately elevated LDL-C in the setting of low inflammation and adequate omega-3 status. The inflammatory context of lipid values is as clinically important as the lipid values themselves.

Conventional vs Functional Medicine Approach

Conventional lipid management focuses primarily on LDL-C reduction through statins, with established evidence for cardiovascular event reduction in high-risk patients. The limitation is that targeting LDL-C as the primary marker misses the atherogenic particle burden measured by ApoB, the inflammatory oxidation of LDL that drives plaque formation, and the upstream metabolic drivers including insulin resistance and thyroid dysfunction that are producing the dyslipidemia. A patient whose LDL-C normalizes on a statin while ApoB remains elevated, hs-CRP is above 2.0 mg/L, and fasting insulin is above 10 mIU/L still has significant residual cardiovascular risk that statin therapy alone does not address.

Domain	Conventional Medicine	Functional Medicine
Primary marker	LDL-C as calculated estimate from standard lipid panel	ApoB as direct particle count; LDL particle number; Lp(a); oxidized LDL alongside standard lipid panel
Inflammatory context	Not routinely assessed in lipid management	hs-CRP and homocysteine as mandatory components of cardiovascular risk characterization
Root cause evaluation	Diet counseling; statins when threshold met	Fasting insulin and HOMA-IR for insulin resistance; TSH and Free T3 for thyroid; omega-3 index for inflammatory lipid oxidation risk
Lp(a)	Not included in standard panel; rarely ordered	Ordered for all patients with family history of early cardiovascular disease or LDL-C not explaining the clinical risk picture
Treatment hierarchy	Statin first; lifestyle as adjunct	Metabolic root cause treatment first; statins when indicated and appropriate; omega-3 and anti-inflammatory interventions as mechanistically targeted additions

Key Labs to Evaluate

A complete evaluation requires markers that characterize both the condition and the upstream drivers producing it.

Advanced Atherogenic Particle Markers

Inflammatory and Metabolic Context

How to Interpret These Labs Together

Pattern	Clinical Implication
Normal LDL-C with elevated ApoB and elevated triglycerides	The discordance pattern from insulin resistance and small dense LDL. Standard lipid management dismisses this as normal risk. True atherogenic burden is elevated and requires metabolic treatment.
LDL-C not responding to statin therapy as expected	Most commonly subclinical hypothyroidism reducing hepatic LDL receptor expression. TSH and Free T3 warranted before escalating lipid-lowering therapy.
Normal LDL-C with family history of early heart disease	Lp(a) testing is the most important next step. Elevated Lp(a) is the most common inherited cardiovascular risk factor that standard panels miss entirely.
Elevated hs-CRP with any lipid abnormality	Inflammatory amplification of cardiovascular risk. Anti-inflammatory interventions including omega-3 repletion and gut dysbiosis treatment are as important as lipid-lowering in this pattern.
Homocysteine above 10 micromol/L	Methylation pathway impairment driving endothelial injury. Correctable with methylated B vitamins: methylfolate, methylcobalamin, and pyridoxal-5-phosphate.

Common Patterns Seen in Patients

• Normal LDL-C with elevated ApoB and elevated triglycerides: the discordance pattern where particle number far exceeds what the cholesterol content suggests; standard lipid management dismisses this patient as normal-risk while their actual atherogenic burden is elevated from insulin resistance and the small dense LDL phenotype that LDL-C cannot detect
• Statin-refractory elevated LDL-C with subclinical hypothyroidism: LDL-C that does not respond adequately to statin therapy because the root cause is reduced hepatic LDL receptor expression from thyroid insufficiency, not LDL overproduction; thyroid optimization resolves the LDL elevation that escalating statin doses cannot
• Elevated Lp(a) discovered in a patient with family history of early heart disease: the most important finding that most patients have never been tested for; Lp(a) is not modifiable by statins or diet and requires aggressive management of all other cardiovascular risk factors to reduce the composite event risk
• Normal LDL-C with elevated coronary artery calcium on imaging: demonstrating that atherosclerosis is progressing through mechanisms that LDL-C is not capturing; ApoB, Lp(a), hs-CRP, and insulin resistance are the most important additional markers to evaluate in this pattern

Treatment and Optimization Strategy

Metabolic Root Cause Treatment as the Primary Intervention

Treating insulin resistance, the root cause of the atherogenic lipid triad in most functional medicine patients, produces the most durable lipid improvements available: triglycerides fall 30 to 50%, HDL rises 10 to 20%, and small dense LDL shifts toward the large buoyant phenotype with metabolic normalization. This is achieved through low glycemic load nutrition, resistance training, berberine (500mg three times daily with meals), and metformin when clinically appropriate. These interventions address the mechanism producing the lipid pattern rather than suppressing the lipid values while the mechanism continues.

What Most Doctors Miss

• Lp(a) is never measured: 20% of the population carries elevated Lp(a), one of the most potent identifiable cardiovascular risk factors, and it is not included in the standard lipid panel ordered for most patients throughout their entire lives; this is a diagnostic gap with direct clinical consequences
• ApoB is not ordered: LDL-C is reported as a calculated estimate that significantly underestimates risk in insulin-resistant patients with the small dense LDL phenotype; ApoB directly counts atherogenic particles and is the superior marker; its absence from standard panels reflects laboratory tradition rather than clinical evidence
• Thyroid evaluation is not included in lipid workup: hypothyroidism is the most common treatable cause of statin-refractory hypercholesterolemia and is not assessed in standard lipid management; adding TSH and Free T3 to every lipid workup would identify a large proportion of patients whose LDL elevation resolves with thyroid optimization
• Insulin resistance is not identified: fasting insulin and HOMA-IR are not included in cardiovascular risk assessment despite insulin resistance being the dominant driver of the most common dyslipidemia pattern and a modifiable root cause that completely changes the treatment approach
• CoQ10 is not repleted in statin patients: statins block the mevalonate pathway, depleting CoQ10 as a direct pharmacological consequence; this depletion drives the muscle-related side effects affecting 5 to 20% of statin users and the mitochondrial energy impairment that contributes to statin-associated fatigue; CoQ10 repletion is mechanistically rational and rarely offered

When to Seek Medical Care

Seek emergency evaluation immediately for any symptoms of acute coronary syndrome including chest pain or pressure, jaw or left arm pain, shortness of breath at rest, or sudden severe sweating with nausea. These represent potential cardiac events requiring immediate evaluation regardless of known lipid status or treatment. For known severely elevated Lp(a), familial hypercholesterolemia with LDL-C above 190 mg/dL, or a strong family history of premature cardiovascular disease, cardiology or lipid specialist evaluation alongside functional medicine root-cause treatment is the appropriate concurrent management approach.

For the broad spectrum of dyslipidemia without acute risk or established cardiovascular disease, functional medicine provides the advanced lipid characterization and upstream driver treatment that standard lipid management does not include and that may determine whether pharmacological intervention is necessary or avoidable through root-cause correction.

Recommended Testing

Frequently Asked Questions

How The Lamkin Clinic Approaches Dyslipidemia

Related Conditions

Related Symptoms